Altay Raises $37 Million for Oral DUX4 Program
Altay Therapeutics closed a $37 million Series A co-led by Sound Bioventures and HealthCap to advance DX5057, an oral small-molecule DUX4 inhibitor, through Phase 1 and Phase 2 proof of concept in facioscapulohumeral muscular…
